vTv Therapeutics Inc (NASDAQ: VTVT) stock rose 31.6% after releasing the results of a multiple ascending dose study for HPP737, an oral PDE4 inhibitor drug that treats psoriasis.
The biotech company revealed that HPP737 demonstrated a favourable safety and tolerability profile without dose-limiting gastrointestinal side effects.
Today’s results build on data from the previous multiple ascending dose study and support the advancement of HPP737 into Phase 2 trials in patients with moderate to severe psoriasis.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
vTv has already held a successful pre-IND meeting with the U.S. Food and Drug Administration’s Dermatology and Dentistry division, supporting the planned IND submission for a Phase 2 study in moderate to severe psoriasis patients.
The trial had 12 participants in two groups randomly given 15mg and 20mg doses of HPP737 or placebo orally once daily over 14 days.
None of the participants had adverse events due to the treatment, which is why vTv believes that it can move forward to develop the drug to achieve anti-inflammatory and anti-psoriatic responses without the significant safety issues of other PDE4 inhibitors.
Investors celebrated the announcements, as evidenced by the premarket rally. Many expect the FDA to okay a phase 2 study of HPP737, which could be a massive milestone for the company.
As it stands, there is little evidence to suggest that the FDA may reject a phase 2 trial; hence, the market’s exuberance is justified in this case.
*This is not investment advice.
vTv Therapeutics stock price.
vTv Therapeutics stock rallied 31.63% premarket to trade at $2.33, rising from Thursday’s closing price of $1.77.
